Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$7.36 - $9.66 $291,102 - $382,072
-39,552 Reduced 65.22%
21,096 $156,000
Q2 2024

Aug 14, 2024

BUY
$7.31 - $10.9 $348,299 - $519,352
47,647 Added 366.49%
60,648 $486,000
Q1 2024

May 14, 2024

SELL
$8.13 - $13.77 $207,672 - $351,740
-25,544 Reduced 66.27%
13,001 $151,000
Q4 2023

Feb 09, 2024

BUY
$6.66 - $16.03 $131,401 - $316,271
19,730 Added 104.86%
38,545 $431,000
Q3 2023

Nov 14, 2023

BUY
$15.06 - $19.41 $128,235 - $165,276
8,515 Added 82.67%
18,815 $291,000
Q2 2023

Aug 14, 2023

BUY
$14.15 - $22.03 $145,745 - $226,909
10,300 New
10,300 $195,000
Q4 2022

Feb 13, 2023

BUY
$5.52 - $12.73 $64,490 - $148,724
11,683 Added 109.4%
22,362 $285,000
Q3 2022

Nov 14, 2022

BUY
$3.02 - $7.0 $32,250 - $74,753
10,679 New
10,679 $62,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $403M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Dynamic Technology Lab Private LTD Portfolio

Follow Dynamic Technology Lab Private LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dynamic Technology Lab Private LTD, based on Form 13F filings with the SEC.

News

Stay updated on Dynamic Technology Lab Private LTD with notifications on news.